Omeros Q2 OMIDRIA rev $28.8M (+37% QoQ); narsoplimab PDUFA Oct 17

OMEROS CORP

2021-Q2 EPS reported -$1.02 revenue$49,885,000

OMIDRIA revenue $28.8M in Q2 2021, up 37% from Q1 $21.1M; net loss narrowed to $28.6M ($0.46/sh) from $35.1M.
Narsoplimab BLA for HSCT-TMA under FDA priority review with PDUFA action date Oct 17, 2021.
Preliminary Phase 1 data for OMS906 (MASP-3 inhibitor) show well tolerated, PK/PD consistent with monthly SC dosing.
CMS proposed rule reaffirms separate payment for OMIDRIA in ASCs for 2022.
Cash & investments $73.7M; $150M ATM program available; $50M line of credit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.